Zacks: Analysts Anticipate Natus Medical Incorporated (BABY) Will Announce Quarterly Sales of $145.85 Million
Equities research analysts expect that Natus Medical Incorporated (NASDAQ:BABY) will announce $145.85 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Natus Medical’s earnings, with the highest sales estimate coming in at $146.20 million and the lowest estimate coming in at $145.50 million. Natus Medical posted sales of $107.70 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 35.4%. The company is scheduled to issue its next earnings results on Wednesday, February 7th.
On average, analysts expect that Natus Medical will report full-year sales of $145.85 million for the current year, with estimates ranging from $515.10 million to $515.70 million. For the next year, analysts anticipate that the business will post sales of $554.10 million per share, with estimates ranging from $552.40 million to $555.80 million. Zacks’ sales averages are an average based on a survey of research firms that cover Natus Medical.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.39 earnings per share.
Several brokerages recently issued reports on BABY. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Tuesday, October 24th. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $46.50.
In related news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares in the company, valued at $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BABY. BlackRock Inc. raised its position in shares of Natus Medical by 0.6% during the 2nd quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock valued at $154,779,000 after buying an additional 25,340 shares during the period. Vanguard Group Inc. raised its position in Natus Medical by 2.9% in the second quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock valued at $87,340,000 after purchasing an additional 66,676 shares during the period. Dimensional Fund Advisors LP raised its position in Natus Medical by 3.3% in the third quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the medical equipment provider’s stock valued at $60,183,000 after purchasing an additional 51,938 shares during the period. Daruma Capital Management LLC raised its position in Natus Medical by 13.1% in the second quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock valued at $54,862,000 after purchasing an additional 169,890 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Natus Medical by 9.7% in the second quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock valued at $36,307,000 after purchasing an additional 86,192 shares during the period. 99.53% of the stock is currently owned by institutional investors and hedge funds.
Natus Medical (NASDAQ:BABY) opened at $41.00 on Tuesday. The company has a market capitalization of $1,289.78, a P/E ratio of 26.71 and a beta of 0.89. Natus Medical has a 52 week low of $31.65 and a 52 week high of $43.85. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.